Cargando…

Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases

Dramatic advancement has been made in recent decades to understand the basis of autoimmunity-mediated neurological diseases. These diseases create a strong influence on the central nervous system (CNS) and the peripheral nervous system (PNS), leading to various clinical manifestations and numerous s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashraf, Hajra, Solla, Paolo, Sechi, Leonardo Atonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504155/
https://www.ncbi.nlm.nih.gov/pubmed/36145298
http://dx.doi.org/10.3390/ph15091077
_version_ 1784796145007984640
author Ashraf, Hajra
Solla, Paolo
Sechi, Leonardo Atonio
author_facet Ashraf, Hajra
Solla, Paolo
Sechi, Leonardo Atonio
author_sort Ashraf, Hajra
collection PubMed
description Dramatic advancement has been made in recent decades to understand the basis of autoimmunity-mediated neurological diseases. These diseases create a strong influence on the central nervous system (CNS) and the peripheral nervous system (PNS), leading to various clinical manifestations and numerous symptoms. Multiple sclerosis (MS) is the most prevalent autoimmune neurological disease while NMO spectrum disorder (NMOSD) is less common. Furthermore, evidence supports the presence of autoimmune mechanisms contributing to the pathogenesis of amyotrophic lateral sclerosis (ALS), which is a neurodegenerative disorder characterized by the progressive death of motor neurons. Additionally, autoimmunity is believed to be involved in the basis of Alzheimer’s and Parkinson’s diseases. In recent years, the prevalence of autoimmune-based neurological disorders has been elevated and current findings strongly suggest the role of pharmacotherapies in controlling the progression of autoimmune diseases. Therefore, this review focused on the current advancement of immunomodulatory drugs as novel approaches in the management of autoimmune neurological diseases and their future outlook.
format Online
Article
Text
id pubmed-9504155
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95041552022-09-24 Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases Ashraf, Hajra Solla, Paolo Sechi, Leonardo Atonio Pharmaceuticals (Basel) Review Dramatic advancement has been made in recent decades to understand the basis of autoimmunity-mediated neurological diseases. These diseases create a strong influence on the central nervous system (CNS) and the peripheral nervous system (PNS), leading to various clinical manifestations and numerous symptoms. Multiple sclerosis (MS) is the most prevalent autoimmune neurological disease while NMO spectrum disorder (NMOSD) is less common. Furthermore, evidence supports the presence of autoimmune mechanisms contributing to the pathogenesis of amyotrophic lateral sclerosis (ALS), which is a neurodegenerative disorder characterized by the progressive death of motor neurons. Additionally, autoimmunity is believed to be involved in the basis of Alzheimer’s and Parkinson’s diseases. In recent years, the prevalence of autoimmune-based neurological disorders has been elevated and current findings strongly suggest the role of pharmacotherapies in controlling the progression of autoimmune diseases. Therefore, this review focused on the current advancement of immunomodulatory drugs as novel approaches in the management of autoimmune neurological diseases and their future outlook. MDPI 2022-08-29 /pmc/articles/PMC9504155/ /pubmed/36145298 http://dx.doi.org/10.3390/ph15091077 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ashraf, Hajra
Solla, Paolo
Sechi, Leonardo Atonio
Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases
title Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases
title_full Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases
title_fullStr Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases
title_full_unstemmed Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases
title_short Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases
title_sort current advancement of immunomodulatory drugs as potential pharmacotherapies for autoimmunity based neurological diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504155/
https://www.ncbi.nlm.nih.gov/pubmed/36145298
http://dx.doi.org/10.3390/ph15091077
work_keys_str_mv AT ashrafhajra currentadvancementofimmunomodulatorydrugsaspotentialpharmacotherapiesforautoimmunitybasedneurologicaldiseases
AT sollapaolo currentadvancementofimmunomodulatorydrugsaspotentialpharmacotherapiesforautoimmunitybasedneurologicaldiseases
AT sechileonardoatonio currentadvancementofimmunomodulatorydrugsaspotentialpharmacotherapiesforautoimmunitybasedneurologicaldiseases